PhaseBio Pharmaceuticals Inc Overview
Pro stress-test →PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company that developed novel therapies for cardiovascular diseases. However, the company filed for Chapter 11 bankruptcy and ceased operations as of September 30, 2024, making it currently defunct.
Strategic Profile
Pro stress-test →The company's pipeline focused on specialized cardiovascular treatments, with bentracimab (PB2452) as its lead candidate, a reversal agent for the antiplatelet drug ticagrelor. Prior to bankruptcy, PhaseBio had received FDA Breakthrough Therapy designation for its lead program but was unable to successfully advance or commercialize its assets.
Competitive Landscape
Pro stress-test →The company competed in the specialized cardiovascular therapeutics space against larger established biopharma companies. Direct competitors in antiplatelet reversal and cardiovascular therapies include major pharmaceutical firms with more extensive pipelines and resources, which contributed to PhaseBio's inability to compete effectively.
Industry Context
PhaseBio Pharmaceuticals Inc operates in Biopharmaceuticals - Cardiovascular Therapeutics.
Key facts
Headquarters: Malvern, US